Thermo Fisher Scientific Inc. (NYSE:TMO) Holdings Cut by Segment Wealth Management LLC

Segment Wealth Management LLC cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 69.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,829 shares of the medical research company’s stock after selling 4,100 shares during the quarter. Segment Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $952,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Charles Schwab Trust Co lifted its holdings in shares of Thermo Fisher Scientific by 25.5% during the 4th quarter. Charles Schwab Trust Co now owns 556 shares of the medical research company’s stock valued at $289,000 after buying an additional 113 shares during the last quarter. Aspiriant LLC increased its position in Thermo Fisher Scientific by 2.6% during the fourth quarter. Aspiriant LLC now owns 1,668 shares of the medical research company’s stock worth $868,000 after buying an additional 43 shares during the last quarter. Reliant Investment Management LLC lifted its position in shares of Thermo Fisher Scientific by 1.7% in the fourth quarter. Reliant Investment Management LLC now owns 12,246 shares of the medical research company’s stock worth $6,371,000 after buying an additional 200 shares during the last quarter. ZWJ Investment Counsel Inc. raised its stake in shares of Thermo Fisher Scientific by 2.6% in the 4th quarter. ZWJ Investment Counsel Inc. now owns 75,152 shares of the medical research company’s stock valued at $39,096,000 after acquiring an additional 1,897 shares in the last quarter. Finally, Pure Financial Advisors LLC boosted its position in Thermo Fisher Scientific by 7.0% during the fourth quarter. Pure Financial Advisors LLC now owns 1,117 shares of the medical research company’s stock worth $581,000 after purchasing an additional 73 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the completion of the sale, the senior vice president now owns 12,736 shares of the company’s stock, valued at approximately $7,134,197.76. The trade was a 13.57 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $530.26, for a total value of $5,302,600.00. Following the sale, the chief executive officer now directly owns 111,192 shares of the company’s stock, valued at approximately $58,960,669.92. This trade represents a 8.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 47,150 shares of company stock worth $25,954,465. Corporate insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

TMO has been the subject of several recent analyst reports. Barclays decreased their price objective on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. StockNews.com raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th. TD Cowen upped their price target on Thermo Fisher Scientific from $656.00 to $686.00 in a report on Tuesday, October 22nd. Redburn Atlantic began coverage on shares of Thermo Fisher Scientific in a research report on Monday, October 14th. They set a “buy” rating and a $680.00 target price on the stock. Finally, Stephens assumed coverage on shares of Thermo Fisher Scientific in a report on Tuesday, October 1st. They set an “overweight” rating and a $680.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $648.95.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $559.72 on Tuesday. Thermo Fisher Scientific Inc. has a 1-year low of $493.30 and a 1-year high of $627.88. The firm’s 50-day moving average price is $529.96 and its two-hundred day moving average price is $568.56. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $214.09 billion, a price-to-earnings ratio of 35.09, a P/E/G ratio of 3.71 and a beta of 0.76.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.03. The firm had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The business’s revenue for the quarter was up .2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.69 EPS. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current fiscal year.

Thermo Fisher Scientific announced that its Board of Directors has authorized a share repurchase plan on Friday, November 15th that permits the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 2% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board of directors believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were given a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.28%. The ex-dividend date of this dividend was Friday, December 13th. Thermo Fisher Scientific’s payout ratio is presently 9.78%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.